Earth Science Tech, Inc. (ETST) Receives Positive
Post# of 333
(Total Views: 323)
Posted On: 12/20/2018 4:41:28 PM
Earth Science Tech, Inc. (ETST) Receives Positive Results from Pre-Launch Testing of Hygee Medical Device, Sets Early 2019 Debut
- ETST has reported successful results in the testing of its unique Hygee medical device for detecting sexually transmitted infections
- Hygee detects chlamydia and is intended to be sold as an at-home kit
- This puts ETST on track to market Hygee in early 2019 through its established distribution channels in multiple countries
- In the future, Hygee may also be certified for gonorrhea testing
Earth Science Tech, Inc. (OTCQB: ETST), a biotech company, has received good news on the development and performance of its Hygee medical device. Molecular diagnostic assays by Procréa Fertility Laboratories have analyzed samples obtained by Hygee and successfully identified the presence of chlamydia, confirming earlier test results on more than 500 women (http://nnw.fm/3WRy0).
ETST, based in Doral, Florida, is focused on the cannabidiol, pharmaceutical and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research. ETST’s goal is to become a world leader in the CBD space.
For the development of Hygee, manufacturing partner Dermagate has already received certification ISO 13485:2013. It opens the way for Hygee’s marketing by early 2019.
In a news release (http://nnw.fm/3WRy0), Michel Aubé, CEO and chief scientific officer of ETST, said, “Hygee is an incredible innovation, and we have partners from many countries waiting to market the device. This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.”
Initially, it will be marketed as an at-home testing device for Chlamydia, ETST said, but it added that R&D efforts in progress indicate that Hygee may soon be certified for gonorrhea testing as well.
ETST also develops and markets hemp-based CBD oil products. The company, and the industry at large, would benefit from the signing of the 2018 Farm Bill by year’s end. That legislation has already has been passed by both houses of Congress, and a provision in it legalizes the growing of industrial hemp in the United States (http://nnw.fm/Kk9Zh).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- ETST has reported successful results in the testing of its unique Hygee medical device for detecting sexually transmitted infections
- Hygee detects chlamydia and is intended to be sold as an at-home kit
- This puts ETST on track to market Hygee in early 2019 through its established distribution channels in multiple countries
- In the future, Hygee may also be certified for gonorrhea testing
Earth Science Tech, Inc. (OTCQB: ETST), a biotech company, has received good news on the development and performance of its Hygee medical device. Molecular diagnostic assays by Procréa Fertility Laboratories have analyzed samples obtained by Hygee and successfully identified the presence of chlamydia, confirming earlier test results on more than 500 women (http://nnw.fm/3WRy0).
ETST, based in Doral, Florida, is focused on the cannabidiol, pharmaceutical and nutraceutical sectors, as well as the development, through subsidiaries, of medical devices and research. ETST’s goal is to become a world leader in the CBD space.
For the development of Hygee, manufacturing partner Dermagate has already received certification ISO 13485:2013. It opens the way for Hygee’s marketing by early 2019.
In a news release (http://nnw.fm/3WRy0), Michel Aubé, CEO and chief scientific officer of ETST, said, “Hygee is an incredible innovation, and we have partners from many countries waiting to market the device. This is only the beginning of realizing the potential of this unique device, and we look forward to updating our shareholders on our progress.”
Initially, it will be marketed as an at-home testing device for Chlamydia, ETST said, but it added that R&D efforts in progress indicate that Hygee may soon be certified for gonorrhea testing as well.
ETST also develops and markets hemp-based CBD oil products. The company, and the industry at large, would benefit from the signing of the 2018 Farm Bill by year’s end. That legislation has already has been passed by both houses of Congress, and a provision in it legalizes the growing of industrial hemp in the United States (http://nnw.fm/Kk9Zh).
ETST holds several wholly owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also formed subsidiary Canno Inno Laboratories Inc., a Montreal, Canada-based company that provides ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)